MedTrace Logo

Evaluation of AP-002 in Patients With Solid Tumors

NCT04143789 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2019-10-31

No results posted yet for this study

Summary

The purpose of this trial is to define an effective and safe dose of AP-002 in advanced or recurrent solid tumors for which there are no standard therapies to use in subsequent studies in advanced or recurrent breast, non-small cell lung cancer (NSCLC) or prostate cancers.

Conditions

Interventions

DRUG

AP-002

Dose escalation

Sponsors & Collaborators

  • Altum Pharmaceuticals INC

    lead INDUSTRY

Principal Investigators

  • Angela Ogden, MD · Altum Pharmaceuticals

Study Design

Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-27
Primary Completion
2021-03-31
Completion
2021-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04143789 on ClinicalTrials.gov